Download PDF

Other users also viewed these articles

One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry Clementina López-Medina; Lucía Otero-Varela; Fernando Sánchez-Alonso; Vega Jovaní; Lorena Expósito-Pérez; Sheila Melchor-Díaz; Yanira Pérez-Vera; Paula Pretel-Ruiz; Javier Manero; Antonio Mera-Varela; Lourdes Mateo; Dolores Ruiz-Montesino; José Andrés Lorenzo-Martín; Teresa Pedraz-Penalva; Isabel Castrejón;
Reumatol Clin. 2025;21:
Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice Jordi Gratacós-Masmitja; Emma Beltrán Catalán; José Luis Álvarez Vega; Ana Urruticoechea-Arana; Concepción Fito; Francisco Maceiras; Joaquín María Belzunegui Otano; Julia Fernández Melón; Eugenio Chamizo Carmona; Miguel Ángel Abad Hernández; Inmaculada Ros Vilamajó; Sonia Castro Oreiro; Eva Pascual Alfonso; Juan Carlos Torre Alonso;
Reumatol Clin. 2024;20:24-31
Liver fibrosis 4 score: Use in the evaluation of non-alcoholic fatty liver disease in patients with psoriatic arthritis Carlota Iñiguez Ubiaga; Carlos García Porrúa; José Antonio Pinto Tasende; Lorena Paula Iñiguez Ubiaga; Amalia Sánchez-Andrade Fernandez;
Reumatol Clin. 2023;19:495-9